Nag Rayapureddi
Analyste en capital-investissement chez LV Management Group, LLC
Provenance du réseau au premier degré de Nag Rayapureddi
Entité | Type d'entité | Industrie | |
---|---|---|---|
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana.
4
| Private Company | Investment Managers | 4 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Nag Rayapureddi via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
ELI LILLY AND COMPANY | Pharmaceuticals: Major | Director of Finance/CFO Chief Tech/Sci/R&D Officer Private Equity Investor | |
Bayer Corp.
Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Serenex, Inc.
Serenex, Inc. Pharmaceuticals: MajorHealth Technology Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member Founder | |
STANDARD BIOTOOLS INC. | Medical Specialties | Director/Board Member | |
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
GLOBEIMMUNE, INC. | Pharmaceuticals: Other | Director/Board Member | |
Conforma Therapeutics Corp.
Conforma Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member | |
Cavion, Inc.
Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Pharmaceuticals: Major | Director/Board Member | |
Cabrellis Pharmaceuticals Corp.
Cabrellis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Cabrellis Pharmaceuticals Corp. manufactures medical products. The firm develops therapies for treatment of cancer. The company was founded by Thomas M. Estok, Lawrence C. Fritz and Christopher C. LeMasters in 2006 and is headquartered in Summit, NJ. | Pharmaceuticals: Major | Director/Board Member | |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | Pharmaceuticals: Major | Director/Board Member | |
SUTRO BIOPHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
AILERON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Biotechnology | Director/Board Member | |
RECEPTOS INC | Pharmaceuticals: Major | Director/Board Member | |
Nimbus Therapeutics LLC
Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
FORMA THERAPEUTICS HOLDINGS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member | |
Esanex, Inc.
Esanex, Inc. Pharmaceuticals: MajorHealth Technology Esanex, Inc. manufactures and develops drugs for cancer treatment. Its products include orally active Hsp90 inhibitors. The company was founded in 2011 and is headquartered in Indianapolis, IN. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Symic Bio, Inc.
Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA. | Biotechnology | Chairman | |
SPYRE THERAPEUTICS, INC. | Biotechnology | Chairman | |
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | Medical Specialties | Director/Board Member | |
Symic Holdings LLC
Symic Holdings LLC BiotechnologyHealth Technology Symic Holdings LLC develops new category of therapeutics. The company was founded by John Paderi, Kate Stuart and Alyssa Panitch and is headquartered in Emeryville, CA. | Biotechnology | Director/Board Member | |
Roche Diagnostics Corp.
Roche Diagnostics Corp. Medical SpecialtiesHealth Technology Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN. | Medical Specialties | Director/Board Member | |
Massachusetts Institute of Technology | College/University | Doctorate Degree | |
Pacific Lutheran University | College/University | Undergraduate Degree | |
University of California, Berkeley | College/University | Doctorate Degree | |
Hydra Biosciences, Inc.
Hydra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA. | Pharmaceuticals: Major | Director/Board Member | |
Trinity Biosystems, Inc.
Trinity Biosystems, Inc. Pharmaceuticals: MajorHealth Technology Trinity Biosystems, Inc. develops and formulates orally delivered bio-therapeutic macromolecules. It offers TriPex system, an approach to macromolecule delivery that works cooperatively with the natural physiology of the body. The system utilizes a specific and natural biological transport mechanism: a receptor-mediated transcellular transport pathway that allows passage through the mucosal epithelium and delivery of the therapeutic payload into the blood. The company was founded by Randall J. Mrsny on July 19, 2002 and is headquartered in Menlo Park, CA. | Pharmaceuticals: Major | Director/Board Member | |
Lilly Research Laboratories
Lilly Research Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Research Laboratories is a company that engages in research and develops medicines. The company is based in Indianapolis, IN. | Miscellaneous Commercial Services | Director/Board Member | |
Numerate, Inc.
Numerate, Inc. Information Technology ServicesTechnology Services Numerate, Inc. operates as a technology platform company that leverages proprietary algorithms and cloud computing to transform the drug design process. The company was founded by Guido Lanza, Nigel P. Duffy, John Hampton Griffin and Brandon Allgood in 2007 and is headquartered in San Francisco, CA. | Information Technology Services | Director/Board Member | |
DNAX Research, Inc. | Corporate Officer/Principal | ||
PROTAGONIST THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Stephen M. Ross School of Business | College/University | Masters Business Admin | |
Lilly Ventures Fund I LLC
Lilly Ventures Fund I LLC Investment ManagersFinance Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements. | Investment Managers | Corporate Officer/Principal | |
COHERUS BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
SURFACE ONCOLOGY, INC. | Biotechnology | Director/Board Member | |
Nimbus Apollo, Inc.
Nimbus Apollo, Inc. Pharmaceuticals: MajorHealth Technology Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
KYMERA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
TEN63 Therapeutics
TEN63 Therapeutics Pharmaceuticals: MajorHealth Technology TEN63 Therapeutics provides drug development services. The American company was founded by Nancy Miller-Rich, Marcel Frenkel, Mark Hallen, Bruce Donald. Marcel Frenkel has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | Biotechnology | Director/Board Member | |
Abshanafelt Advisory | President | ||
Vioplore Management LLC | Private Equity Investor | ||
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
Etats-Unis | 50 |
Australie | 2 |
Sectorielle
Health Technology | 40 |
Consumer Services | 4 |
Technology Services | 3 |
Finance | 3 |
Commercial Services | 2 |
Opérationnelle
Director/Board Member | 40 |
Independent Dir/Board Member | 9 |
Private Equity Investor | 6 |
Corporate Officer/Principal | 6 |
Undergraduate Degree | 3 |
Relations les plus connectées
Insiders | |
---|---|
S. Torres | 21 |
Steve Hall | 19 |
Armen Shanafelt | 17 |
Julie Gilmore | 4 |
- Bourse
- Insiders
- Nag Rayapureddi
- Connexions Sociétés